Positive readout? Public offering: Viridian plans to raise $175M on eye disease therapy data
16 Aug 2022
Antibody
A year and a half after rebranding, Viridian Therapeutics appears to have found a path forward.
On Monday, the Waltham, MA-based biotech
reported initial data
from its Phase I/II trial of thyroid eye disease (TED) — and the results, while only in one of three treatment arms, look promising thus far. Later in the day, Viridian
followed up
with a public offering of $175 million in both common and preferred stock.
In a small cohort of a Phase I/II trial, 5 of 6 patients who got 10 mg/kg of Viridian’s thyroid eye disease candidate — an anti-IGF-1R antibody known as VRDN-001— responded to treatment, meaning they had a ≥2mm reduction in the bulging of their eyes, a common symptom of the disease, alongside at least a 2-point reduction (out of 7) on a composite score of TED-related symptoms. Two patients in the cohort received placebo.
In addition, three-quarters of patients who had double vision from TED saw symptoms resolved as well.
In this treatment arm, there were no serious adverse events or discontinuations reported, but two patients had muscle spasms and one had ringing in their ear, though none required additional intervention, the biotech said.
Viridian plans to read out the 20 mg/kg and 3 mg/kg arms of the trial later in the year.
Horizon’s Tepezza, also an anti-IGF-1R antibody, became the
first approved treatment
for thyroid eye disease in early 2020. Tepezza is one of Horizon’s top-selling drugs, bringing in almost $480 million last quarter. However, in Horizon’s Q2 call earlier this month, CEO Tim Walbert lowered 2022 sales predictions for the drug, down from around $4 billion to between $3.53 billion and $3.6 billion.
“We expected Tepezza trends to continue to show the positive progress based on the post-Omicron recovery and that didn’t happen,” Walbert said during the call.
Viridian CMO Barrett Katz said of VRDN-001:
In addition to Viridian’s public offering of $175 million, underwriters can go back for another $26.25 million in shares of its common stock.
In 2020, Viridian, then known as miRagen,
slashed its workforce
in half, shuffled its executive leadership, and sidelined its discovery work. The penny stock biotech
bought out
Viridian Therapeutics, adopting its name and a new ticker symbol a few months later. Alongside the buyout and rebranding, what was formerly a microRNA biotech in miRagen pivoted its focus to Viridian’s TED pipeline.
In response to Monday’s readout, Viridian’s stock
$VRDN
has jumped nearly 60%, from around $15 to nearly $25 Tuesday morning.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.